FIZE Medical's $36M War Chest to Redefine ICU Patient Monitoring

NEW YORK, NY – March 30, 2026 – FIZE Medical, a MedTech innovator focused on critical care, has solidified its financial position to accelerate a global expansion, announcing that the exercise of stock warrants by existing investors has infused an additional $6 million into the company. This move, which brings its total Series A financing to a robust $36 million, signals powerful investor conviction in the company's mission to transform fluid management in intensive care units (ICUs) from a reactive practice into a proactive, data-driven science.

The proceeds are earmarked for an ambitious three-pronged strategy: accelerating the commercial adoption of its FIZE kUO® system across the United States, Europe, and Japan; fueling research and development into next-generation, AI-powered predictive analytics; and expanding the clinical evidence base through new studies at leading hospitals. This strategic capital injection underscores a pivotal moment for the company as it aims to set a new standard of care for the world's most vulnerable patients.

A Resounding Vote of Investor Confidence

The decision by select existing investors to exercise their warrants at the original price is more than just a financial transaction; it is a significant endorsement of FIZE Medical's technology, market strategy, and leadership. This act demonstrates a deep-seated belief in the company's growth trajectory and its potential to capture a significant share of the estimated $12 billion annual market for AI-based technologies in critical care.

The company's investor base includes strategic partners like Rapha Capital Management, whose president also serves as FIZE Medical's Chairman, bringing deep expertise in disruptive healthcare technologies. Other key backers such as Valitas Venture Capital and eHealth Ventures contribute crucial go-to-market strategy and global distribution channel access, respectively. This syndicate provides not just capital, but a network of expertise essential for navigating the complex global MedTech landscape.

"This $6 million investment is a powerful vote of confidence from our partners – not just in our technology, but in FIZE's overall capabilities and our proven track record of delivering high-impact solutions to ICUs worldwide," said Dror Zerem, CEO of FIZE Medical, in a statement. "With this capital, we are accelerating the development of predictive capabilities that will enable clinicians to intervene earlier and ultimately improve patient outcomes."

This infusion builds upon a previously successful $30 million Series A round, providing the necessary firepower to scale operations and solidify its market position against competitors in the fluid management space, such as Observe Medical and Serenno Medical.

The Clinical Imperative: Shifting from Reaction to Prevention

At the heart of FIZE Medical's mission is a critical, often-overlooked challenge in the ICU: the precise management of patient fluids. Imbalances can lead to severe complications, with Acute Kidney Injury (AKI) being one of the most dangerous. Approximately 50% of all ICU patients develop AKI, a condition linked to mortality rates exceeding 20%. Traditionally, monitoring urine output has been a manual, intermittent process, leaving clinicians to react to problems only after they have manifested.

FIZE Medical's flagship FIZE kUO system directly confronts this issue by automating the process and providing a continuous, real-time stream of data on kidney urine output. This subtle but critical distinction—monitoring the kidneys' direct output rather than what has collected in the bladder—offers a far more immediate and accurate indicator of a patient's hemodynamic status and renal function. The data is streamed minute-by-minute to bedside monitors and integrated into the hospital's electronic medical records (EMR), providing alerts that flag subtle changes indicative of impending kidney deterioration.

This allows clinical teams to intervene hours earlier than with traditional methods, potentially preventing irreversible kidney damage and other life-threatening complications like circulatory shock. The system has already been used to monitor over 4,000 patients in leading hospitals across the United States and Israel, demonstrating its real-world value. The company has secured key contracts with major healthcare group purchasing organizations like Vizient and Premier's Kiindo™ Alliance, facilitating its adoption in the competitive U.S. market.

The AI Frontier: Predicting Crises Before They Happen

While real-time monitoring represents a significant leap forward, FIZE Medical is already focused on the next horizon: predictive analytics. The fresh funding will heavily resource the company's R&D efforts to build out its AI-driven platform, transforming the FIZE kUO from a monitoring device into an intelligent Decision Support System (DSS).

The vision is to leverage the vast amounts of high-fidelity data collected by the kUO system to train sophisticated algorithms capable of predicting patient deterioration. Instead of merely alerting a clinician that a patient's kidney function is declining, the future system aims to forecast that decline hours in advance, providing insights into the probable cause and suggesting potential therapeutic adjustments.

This AI layer will analyze complex patterns that are invisible to the human eye, integrating data points to create a comprehensive, predictive picture of a patient's status. The company plans to expand the platform's capabilities to include advanced patient condition predictions and intra-abdominal pressure measurement, another key vital sign in critical care. By empowering clinicians with predictive insights, the technology promises not only to improve patient safety but also to streamline clinical workflows and reduce the cognitive burden on overburdened ICU staff.

Charting a Global Course for a New Standard of Care

With a strengthened balance sheet and a proven product, FIZE Medical is aggressively pursuing a global commercialization strategy. The capital will be deployed to accelerate market penetration in the U.S. while launching concerted entries into the highly regulated but lucrative European and Japanese markets. This expansion requires navigating the distinct regulatory pathways of the FDA in the U.S., the EU's stringent Medical Device Regulation (MDR), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

A significant portion of the funds will support the expansion of clinical validation studies, which are essential for securing these regulatory approvals and convincing clinical stakeholders of the technology's efficacy and economic value. To meet the anticipated global demand, the company is also scaling up its production infrastructure in both Israel and Vietnam.

By building a robust body of clinical evidence and establishing a worldwide commercial footprint, FIZE Medical is not just selling a device; it is advocating for a fundamental shift in the philosophy of critical care. The company's journey from a promising startup to a well-funded international player illustrates a clear trend in modern medicine: the convergence of digital monitoring, data analytics, and artificial intelligence to create a more proactive, precise, and ultimately more humane standard of patient care.